Clinical trials: Glioma, Malignant
Brain Tumors, Central Nervous System Tumors
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107471
- Testing
- filgrastim, topotecan hydrochloride, radiation therapy
- Where
- 80 sites in United States, Australia and 2 more
- Volunteers
- 7 people
- Sponsor
- Children's Oncology Group
Diffuse Glioma, Radionecrosis of Brain
A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
Diffuse gliomas are common tumors involving the brain. They are usually treated by surgery followed by radiation and chemotherapy. Radiotherapy is used for the treatment of brain tumors which causes damage to the tumor cells.
- Conditions
- Diffuse Glioma, Radionecrosis of Brain, High Grade Glioma, Glioblastoma Multiforme
- Trial name
- CHROME (NCT06016452)
- Testing
- Chlorophyllin
- Where
- India
- Volunteers
- 118 people
- Sponsor
- Tata Memorial Centre
Glioma, Astrocytoma
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12…
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma, Glioblastoma
- Trial name
- NCT00392171
- Testing
- Temozolomide
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent High-grade Glioma
AsiDNA Children, Adolescents and Young Adults
HGG comprises diffuse midline gliomas (DMG), including diffuse infiltrating brainstem glioma (DIPG), characterised by histone gene mutations, as well as non-DM HGGs mainly in non-midline supratentorial areas, with distinct…
- Trial name
- AsiDNA (NCT05394558)
- Testing
- AsiDNA
- Where
- 10 sites in France
- Volunteers
- 8 people
- Sponsor
- Institut Curie
Malignant Glioma
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
- Trial name
- NCT00953121
- Testing
- bevacizumab and CPT-11 and Carboplatin
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Annick Desjardins
Glioblastoma, Glioma, Malignant
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM
The primary purpose of this study is to determine the maximum tolerated dose (MTD) of MT-201-GBM (pp65CMV antigen monocytes) that will be administered to patients newly diagnosed with a type of brain tumor called glioblastoma…
- Trial name
- DEMAND (NCT04741984)
- Testing
- MT-201-GBM monocyte vaccine
- Sponsor
- Michael Gunn
Brain and Central Nervous System Tumors
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005855
- Testing
- carmustine, efaproxiral
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioma, Astrocytoma
Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
This clinical trial will study the safety and effectiveness of an engineered herpes virus, G207, administered directly into the brain of patients with recurrent brain cancer.
- Conditions
- Glioma, Astrocytoma, Glioblastoma
- Trial name
- NCT00028158
- Testing
- G207, an oncolytic virus
- Volunteers
- 65 people
- Sponsor
- MediGene
Glioblastoma, Malignant Solid Neoplasm
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors.
- Trial name
- NCT04822688
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Thomas Jefferson University
Brain and Central Nervous System Tumors
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irofulven in treating patients who have progressive…
- Trial name
- NCT00012038
- Testing
- irofulven
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade glioma or brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01234740
- Testing
- bafetinib, microdialysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, Astrocytoma
Venous Thromboembolism Prevention in Outpatients With Glioma
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
- Conditions
- Glioblastoma, Astrocytoma, Venous Thromboembolism
- Trial name
- VTE-POG (NCT05683808)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Vermont Medical Center
Glioma, Malignant
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Glioma is a common brain tumor with a high risk of venous thromboembolism during treatment, especially in the months after surgery.
- Trial name
- NCT06196918
- Testing
- Rivaroxaban 10 MG
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Low Grade Glioma, Malignant Brain Glioma
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor.
- Conditions
- Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm, Meningioma
- Trial name
- NCT06132685
- Testing
- Biospecimen Collection, Computed Tomography, Dexamethasone
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Emory University
Glioblastoma, Gliosarcoma
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Primary objective: To determine the 6-month progression free survival of patients with recurrent glioblastoma multiforme (GBM) treated with Erlotinib plus Sirolimus.
- Trial name
- NCT00672243
- Testing
- Erlotinib + sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Brain Cancer, Central Nervous System Diseases
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
The goal of this clinical research study is to find the highest tolerable dose of DNX-2401 that can be injected directly into brain tumors and into the surrounding brain tissue where tumor cells can multiply.
- Trial name
- NCT00805376
- Testing
- DNX-2401, Tumor Removal
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- DNAtrix, Inc.
Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
- Conditions
- Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG
- Trial name
- NCT06838676
- Testing
- ACT001
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Nationwide Children's Hospital
Brain Neoplasms, Glioma
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463203
- Testing
- Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 54 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Malignant Glioma, Glioblastoma
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
This is a Phase 1/2 clinical trial to evaluate a new combination of drugs, marizomib (MRZ) and bevacizumab (BEV; Avastin®), for the treatment of WHO Grade IV malignant glioma.
- Trial name
- NCT02330562
- Testing
- MRZ, BEV
- Where
- 5 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Celgene
Brain and Central Nervous System Tumors
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT00352313
- Testing
- ATN-161, carboplatin
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.